Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
Type:
Grant
Filed:
January 30, 2007
Date of Patent:
February 28, 2012
Assignee:
Argos Therapeutics, Inc.
Inventors:
Alexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
Type:
Application
Filed:
January 21, 2011
Publication date:
January 19, 2012
Applicant:
ARGOS THERAPEUTICS, INC.
Inventors:
Alexander STEINKASSERER, Matthias Lechmann, Elisabeth Zinser
Abstract: The invention provides CD4+CD25? T cells and Tr1-like regulatory T cells (i.e., contact-independent Type 1-like regulatory T cells), processes for their production and their use for regulatory purposes.
Abstract: A system and method for automated processing of nucleic acids and other samples includes a disposable container comprising a tray and a flexible barrier. The barrier is configured to seal with a top edge of the tray, providing a closed, aseptic work area within the sealed tray. A pipette head and/or other sample manipulation device can be attached to the inside of the barrier, and the barrier can include an interface for a robotic arm or other device. When the barrier is sealed over the tray, the barrier separates the contents of the tray from the robot or other manipulation device. The barrier can be flexible, and allow the robotic arm to move the pipette head throughout the work area of the tray. All samples, reagents, pipette tips and other tools or devices for processing nucleic acid samples may remain within the closed compartment provided by the container during processing.
Type:
Grant
Filed:
January 17, 2007
Date of Patent:
October 4, 2011
Assignee:
Argos Therapeutics, Inc.
Inventors:
Simon Jonathon Spence, Richard Alexander Grant, Timothy Doyle Peele, William Samuel Hunter, Ashraf F. Abdelmoteleb, David Thomas Kneen, Robert Alister Neil, Simon Harris
Abstract: A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.
Type:
Grant
Filed:
July 17, 2008
Date of Patent:
April 12, 2011
Assignees:
Argos Therapeutics, Inc., The Rockefeller University
Inventors:
Ralph M. Steinman, Kayo Inaba, Gerold Schuler
Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
Type:
Grant
Filed:
November 19, 2003
Date of Patent:
February 22, 2011
Assignee:
Argos Therapeutics, Inc.
Inventors:
Alexander Steinkasserer, Matthias Lechmann, Elizabeth Zinser
Abstract: A method for eliciting an immune response to an antigen in a subject via (a) loading isolated antigen presenting cells with an antigen ex vivo; and (b) administering the antigen presenting cells to a subject at a pre-treated site.
Type:
Grant
Filed:
December 10, 2003
Date of Patent:
August 31, 2010
Assignees:
Argos Therapeutics, Inc., Duke University
Abstract: We describe an improved method for generating sizable numbers of mature dendritic cells from nonproliferating progenitors in human blood. The first step or “priming” phase is a culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4 to produce immature dendritic cells. The second step or “differentiation” phase requires the exposure to dendritic cell maturation factor such as monocyte conditioned medium. Using this two-step approach, substantial yields are obtained. The dendritic cells derive from this method have all the features of mature cells. They include a stellate cell shape, nonadherence to plastic, and very strong T cell stimulatory activity. The mature dendritic cells produced according to this invention are useful for activating T cells.
Type:
Grant
Filed:
February 12, 1996
Date of Patent:
February 9, 2010
Assignees:
Argos Therapeutics, Inc., The Rockefeller University
Inventors:
Ralph M. Steinman, Nina Bhardwaj, Gerold Schuler
Abstract: The invention relates to T cells transiently transfected with RNA, especially RNA encoding a T cell receptor and/or FoxP3, and to methods of transfecting T cells with RNA by electroporation. Compositions of the invention include an effector T cell transiently transfected with RNA encoding a T cell receptor (TCR) specific for an antigen, wherein the T cell demonstrates effector function specific for cells presenting the antigen in complex with an MHC molecule. Treg cells comprising an exogenous RNA encoding FoxP3 are also provided. The transfected T cells are useful for immunotherapy, particularly in the treatment of tumors, pathogen infection, autoimmune disease, transplant rejection and graft versus host disease.
Type:
Application
Filed:
December 11, 2006
Publication date:
September 10, 2009
Applicant:
Argos Therapeutics, Inc.
Inventors:
Gerold Schuler, Jan Dörrie, Niels Schaft
Abstract: This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be used to identify the pathogen variants present in a sample, to quantitate the pathogen present in a sample, and as a nucleic acid vaccine, or in the preparation of antigen presenting cell vaccines. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can be used to transfect/load antigen presenting cells. The loaded antigen presenting cells can then be used as a vaccine for the treatment of pathogen infection. In another embodiment, nucleic acids produced by the methods of the invention can be used directly as nucleic acid vaccines without prior loading into antigen presenting cells.
Type:
Application
Filed:
September 14, 2005
Publication date:
December 18, 2008
Applicants:
ARGOS THERAPEUTICS, INC., KIRIN BEER KABUSHIKI KAISHA
Inventors:
Charles Nicolette, Irina Tcherepanova, Jason Harris, Donald Healey
Abstract: A method of amplifying RNA to obtain RNA molecules that are predominantly in the sense orientation and essentially devoid of RNA molecules that are in the anti-sense orientation. A method of transfecting antigen presenting cells with a composition comprising sense RNA encoding immunogenic antigens and essentially devoid of antisense RNA and dsRNA is also provided as well as dendritic cells prepared according to the method.
Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
Type:
Application
Filed:
January 30, 2007
Publication date:
September 13, 2007
Applicant:
ARGOS THERAPEUTICS INC
Inventors:
Alexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
Abstract: We describe an improved method for generating sizable numbers of mature dendritic cells from nonproliferating progenitors in human blood. The first step or “priming” phase is a culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4 to produce immature dendritic cells. The second step or “differentiation” phase requires the exposure to dendritic cell maturation factor such as monocyte conditioned medium. Using this two-step approach, substantial yields are obtained. The dendritic cells derive from this method have all the features of mature cells. They include a stellate cell shape, nonadherence to plastic, and very strong T cell stimulatory activity. The mature dendritic cells produced according to this invention are useful for activating T cells.
Type:
Grant
Filed:
January 15, 2002
Date of Patent:
April 3, 2007
Assignees:
The Rockefeller University, Argos Therapeutics, Inc.
Inventors:
Ralph M. Steinman, Nina Bhardwaj, Gerold Schuler